Prediction of tumour uptake of therapeutic docetaxel using [11C]docetaxel and PET-CT

Prediction of tumour uptake of therapeutic docetaxel using [11C]docetaxel and PET-CT - Effect of therapeutic docetaxel on [11C]docetaxel uptake in tumours

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33256

Enrollment

Registered

2009-12-01

Start date

2010-03-15

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced solid tumour

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age: 18 years of age or older - Patients with an advanced solid tumour planned to receive docetaxel treatment - Disease with a malignant lesion >= 1.5 cm diameter within the chest as measured by Response Evaluation Criteria in Solid Tumors (RECIST) - Life expectancy of at least 12 weeks - ECOG performance status of 0 - 2 - Neutrophils > 1.5 x 109/L - Haemoglobin > 6.0 mmol/l - Able to comply with study procedures - Written Informed Consent

Exclusion criteria

Exclusion criteria: - Previous treatment with taxanes - Claustrophobia - Pregnant or lactating patients - Patients having metal implants (e.g. pacemakers) - Concurrent treatment with experimental drugs

Design outcomes

Primary

Measure	Time frame
Change in [11C]docetaxel uptake by tumours after administration of therapeutic docetaxel.	—

Secondary

Measure	Time frame
1) Change in venous metabolite fractions of [11C]docetaxel after administration of therapeutic docetaxel. 2) The relation between [11C]docetaxel uptake and blood flow in tumours after administration of therapeutic docetaxel.	—

Countries

Netherlands

Outcome results